Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3949/ccjm.87a.ccc056 http://scihub22266oqcxt.onion/10.3949/ccjm.87a.ccc056 32759176!ä!32759176 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cleve+Clin+J+Med 2020 ; 87 (11): 664-670 Nephropedia Template TP {{tp|p=32759176|t=2020. Convalescent plasma for COVID-19: Promising, not proven |pdf=|usr=}}{{32759176}} gab.com Text Convalescent plasma for COVID-19: Promising, not proven JO: Cleve Clin J Med http://www.kidney.de/pget.php?&tw=1&pmid=32759176 #FOAvip While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials. Twit Text FOAVip Convalescent plasma for COVID-19: Promising, not proven ????Cleve Clin J Med http://www.kidney.de/pget.php?&tw=1&pmid=32759176 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32759176 #FOAvip English Wikipedia <ref>{{Cite pmid|32759176}}</ref> Convalescent plasma for COVID-19: Promising, not proven #MMPMID32759176 Mucha SR; Quraishy N Cleve Clin J Med 2020[Nov]; 87 (11): 664-670 PMID32759176show ga While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials. |*Betacoronavirus/immunology/isolation & purification[MESH] |*Coronavirus Infections/diagnosis/genetics/immunology/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/diagnosis/genetics/immunology/therapy[MESH] |*Time-to-Treatment[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques/*methods[MESH] |Clinical Trials as Topic[MESH] |Donor Selection[MESH] |Humans[MESH] |Immunization, Passive/adverse effects/methods[MESH] |Patient Selection[MESH] |Predictive Value of Tests[MESH] |Reproducibility of Results[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH]Convalescent plasma for COVID-19: Promising, not proven (epmc).pdf DeepDyve Pubget Overpricing